Management of Rh-Negative G1P0 at 15 Weeks Gestation
For an Rh-negative primigravida at 15 weeks with an ongoing pregnancy, confirm her Rh-negative status and antibody screen now, then administer routine antenatal RhIG prophylaxis at 28 weeks gestation (300 mcg IM or IV), followed by postpartum prophylaxis within 72 hours of delivery if the infant is Rh-positive.
Current Management at 15 Weeks
At this gestational age with an uncomplicated ongoing pregnancy, no RhIG administration is indicated at this time 1. Your immediate actions should include:
- Confirm blood type and antibody screen if not already done at the first prenatal visit
- Document Rh-negative status clearly in the medical record
- Ensure she is not already alloimmunized (negative antibody screen)
- Consider paternal Rh testing to determine if prophylaxis will be needed (if father is Rh-negative, no prophylaxis is necessary) 1
Important caveat: Women with "weak D" (formerly Du-positive) phenotype should NOT receive RhIG and should be managed as Rh-positive 2.
Routine Antenatal Prophylaxis Protocol
At 28 weeks gestation, administer RhIG 300 mcg (1500 IU) IM or IV to prevent antepartum alloimmunization 1. This reduces the risk of alloimmunization from 1.8% to 0.1-0.2% 3.
Alternative dosing: Two doses of 120 mcg—one at 28 weeks and one at 34 weeks—though 300 mcg at 28 weeks is standard in North America 2.
Repeat antibody screen at 28 weeks before administering RhIG 1.
Postpartum Management
Within 72 hours of delivery, if the infant is Rh-positive:
- Administer RhIG 300 mcg IM or IV
- Test for fetomaternal hemorrhage (FMH) to determine if additional doses are needed
- If FMH exceeds 15 mL of fetal red blood cells (30 mL whole blood), give additional 10 mcg RhIG per 0.5 mL of fetal RBCs 2, 1
If RhIG is not given within 72 hours, it should still be administered up to 28 days postpartum, though efficacy decreases 2.
Indications for RhIG Before 28 Weeks
RhIG is indicated at 15 weeks only if a potentially sensitizing event occurs:
Events Requiring RhIG at 15 Weeks (300 mcg dose):
- Amniocentesis 2, 1
- Chorionic villus sampling (if performed after 12 weeks) 2
- Spontaneous or threatened abortion 2, 1
- Induced abortion 2, 1
- Ectopic pregnancy 2
- Vaginal bleeding with potential placental disruption 1
- Abdominal trauma 2, 1
- Any invasive prenatal procedure 2
Critical timing: RhIG should be given as soon as possible after a sensitizing event, ideally within 72 hours, but can be given up to 28 days 2.
Special Considerations for First Trimester Events
The 2024 SMFM guidelines 3 specifically address events before 12 weeks, noting controversy exists. While some organizations (WHO, Society of Family Planning) recommend against routine RhIG before 12 weeks due to cost and access concerns, SMFM recommends offering RhIG even for events before 12 weeks when logistically feasible, given that fetal RBCs express D-antigen as early as 6 weeks gestation.
At 15 weeks gestation (second trimester), there is no controversy—RhIG is definitively indicated for any sensitizing event with a dose of 300 mcg 2, 1.
Dosing Summary by Gestational Age
- Before 12 weeks: Minimum 120 mcg (if event occurs)
- 12-28 weeks: 300 mcg (if sensitizing event occurs)
- 28 weeks: 300 mcg (routine antenatal prophylaxis)
- Postpartum: 300 mcg (if infant Rh-positive)
Common Pitfalls to Avoid
- Do not give RhIG to women with "weak D" phenotype—they should be managed as Rh-positive 2
- Do not skip the 28-week dose even if no complications have occurred—antepartum prophylaxis is essential 1
- Do not forget to test for FMH postpartum after high-risk events (trauma, abruption, manual placental removal) as standard doses may be insufficient 2, 1
- Do not withhold RhIG if 72 hours have passed—give it anyway up to 28 days 2
- Do not repeat the 28-week dose at 40 weeks unless the initial dose was given before 28 weeks 2
Patient Counseling
Obtain verbal or written informed consent before administering RhIG, as it is a blood product 2. Explain that:
- RhIG prevents antibody formation that could harm future pregnancies
- Without prophylaxis, risk of alloimmunization is 13-17% postpartum and 1.8% antepartum
- With prophylaxis, risk drops to <1% overall
- The medication is derived from human plasma but is screened and sterilized